Qiwi PLC (QIWI) Reaches $19.72 After 4.00% Up Move; 683 Capital Management Raised Alnylam Pharmaceuticals (ALNY) Stake By $5.55 Million

August 7, 2017 - By Maria Brooks

683 Capital Management Llc increased Alnylam Pharmaceuticals Inc (ALNY) stake by 125% reported in 2016Q4 SEC filing. 683 Capital Management Llc acquired 150,000 shares as Alnylam Pharmaceuticals Inc (ALNY)’s stock rose 48.45%. The 683 Capital Management Llc holds 270,000 shares with $10.11M value, up from 120,000 last quarter. Alnylam Pharmaceuticals Inc now has $7.61B valuation. The stock rose 0.86% or $0.71 reaching $83.15 per share. About 68,123 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since August 7, 2016 and is uptrending. It has outperformed by 16.84% the S&P500.

The stock of Qiwi PLC (NASDAQ:QIWI) is a huge mover today! About 89,718 shares traded. Qiwi PLC (NASDAQ:QIWI) has risen 82.66% since August 7, 2016 and is uptrending. It has outperformed by 65.96% the S&P500.The move comes after 6 months positive chart setup for the $1.20B company. It was reported on Aug, 7 by Barchart.com. We have $20.51 PT which if reached, will make NASDAQ:QIWI worth $48.00M more.

Investors sentiment decreased to 0.77 in 2016 Q4. Its down 0.25, from 1.02 in 2016Q3. It fall, as 64 investors sold ALNY shares while 65 reduced holdings. 35 funds opened positions while 64 raised stakes. 78.05 million shares or 3.80% more from 75.19 million shares in 2016Q3 were reported. Aqr Ltd Liability Co owns 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 27,669 shares. Blackrock owns 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 13,617 shares. Bnp Paribas Arbitrage Sa has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Dekabank Deutsche Girozentrale, a Germany-based fund reported 40,510 shares. Manufacturers Life Insur The holds 2,374 shares. Loring Wolcott & Coolidge Fiduciary Advsrs Ltd Liability Partnership Ma has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Baystate Wealth Mgmt holds 0% or 460 shares in its portfolio. Royal Commercial Bank Of Canada holds 0% or 3,409 shares. First Personal Finance holds 0% or 219 shares in its portfolio. Fic Inc has 172,242 shares. Us Fincl Bank De has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Granite Point Management LP holds 3.28% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 110,000 shares. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Inv Mngmt accumulated 14,900 shares or 0.01% of the stock. Tarbox Group Inc invested in 0% or 20 shares. Tower Research Capital Lc (Trc) accumulated 1,637 shares or 0.01% of the stock.

Since May 15, 2017, it had 2 buys, and 3 selling transactions for $17.81 million activity. 297,501 shares were bought by Sanofi, worth $21.38M on Wednesday, May 31. Vaishnaw Akshay also sold $825,000 worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares. On Tuesday, May 16 the insider Mason Michael sold $656,250. KEATING LAURIE bought $751,502 worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Tuesday, May 30.

683 Capital Management Llc decreased Procter And Gamble Co (Put) (NYSE:PG) stake by 50,000 shares to 50,000 valued at $4.20 million in 2016Q4. It also reduced Wisdomtree Tr (EPI) stake by 480,000 shares and now owns 30,000 shares. Capital One Finl Corp (NYSE:COF) was reduced too.

Among 21 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 13 have Buy rating, 0 Sell and 8 Hold. Therefore 62% are positive. Alnylam Pharmaceuticals had 49 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Tuesday, May 3 by Leerink Swann. On Thursday, February 2 the stock rating was initiated by Ladenburg Thalmann with “Buy”. The stock has “Outperform” rating by Leerink Swann on Tuesday, February 16. Barclays Capital downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Thursday, October 6. Barclays Capital has “Equal-Weight” rating and $50 target. The firm earned “Hold” rating on Saturday, August 22 by TheStreet. The firm has “Overweight” rating given on Friday, August 5 by JP Morgan. The firm has “Buy” rating given on Thursday, October 6 by Jefferies. The firm has “Buy” rating by Chardan Capital Markets given on Wednesday, November 30. The company was initiated on Tuesday, August 11 by FBR Capital. As per Monday, August 31, the company rating was maintained by Piper Jaffray.

Analysts await Qiwi PLC (NASDAQ:QIWI) to report earnings on August, 10. They expect $0.24 earnings per share, down 27.27% or $0.09 from last year’s $0.33 per share. QIWI’s profit will be $14.60M for 20.54 P/E if the $0.24 EPS becomes a reality. After $0.37 actual earnings per share reported by Qiwi PLC for the previous quarter, Wall Street now forecasts -35.14% negative EPS growth.